文献速递其他结缔组织病

EuroMyositis登记库:促进特发性炎性肌病研究的国际合作工具

The EuroMyositis registry: an international collaborative tool to facilitate myositis research.
PubMed 文献 · Ann Rheum Dis · 2017-08-30

该研究基于11个国家3067例特发性炎性肌病(IIM)病例的横断面分析,评估临床亚型、肌外受累、环境暴露与用药之间的关联。结果显示吸烟与间质性肺病、吞咽困难、恶性肿瘤及心脏受累相关,肌外受累与HAQ评分升高相关,提示IIM为多系统炎性疾病。

要点

  • 吸烟与IIM患者间质性肺病、吞咽困难、恶性肿瘤及心脏受累风险升高相关。
  • 吞咽困难发生率为39%,心脏受累为9%,两者均与HAQ评分升高相关。
  • 间质性肺病发生率30%,在抗合成酶综合征中最高达71%。

核心结论

  • IIM患者肌外受累常见且与吸烟相关,并影响疾病严重程度,提示IIM为多系统炎性疾病。

研究设计与样本

  • 对来自11个国家的3067例IIM病例进行横断面分析,探讨临床亚型、肌外受累、环境暴露与药物之间的关联。

主要发现

  • 3067例IIM中女性占69%,最常见亚型为皮肌炎(31%)。
  • 吸烟在结缔组织病重叠病例中更常见(45%,OR 1.44,95%CI 1.09–1.90,p=0.012)。
  • 吸烟与间质性肺病(OR 1.32,95%CI 1.06–1.65,p=0.013)、吞咽困难(OR 1.43,95%CI 1.16–1.77,p=0.001)、恶性肿瘤(OR 1.78,95%CI 1.36–2.33,p<0.001)及心脏受累(OR 2.40,95%CI 1.60–3.60,p<0.001)相关。
  • 吞咽困难发生率为39%,心脏受累为9%,两者发生与HAQ评分升高相关(校正OR 1.79,95%CI 1.43–2.23,p<0.001)。
  • 包涵体肌炎病例HAQ评分更高(校正OR 3.85,95%CI 2.52–5.90,p<0.001);恶性肿瘤 occurred in 13%,皮肌炎中为20%(OR 2.06,95%CI 1.65–2.57,p<0.001);间质性肺病发生率为30%,抗合成酶综合征中为71%(OR 10.7,95%CI 8.6–13.4,p<0.001)。

关键数值与推荐

  • 成人型与幼年型皮肌炎皮疹特征不同:V征在成人皮肌炎为56%,幼年型皮肌炎为16%(OR 0.16,95%CI 0.07–0.36,p<0.001)。
  • 糖皮质激素使用率为98%,甲氨蝶呤为71%,硫唑嘌呤为51%。

临床怎么用

  • 临床应关注IIM患者肌外受累(尤其吞咽困难、心脏受累、间质性肺病和恶性肿瘤),并将其纳入预后评估与临床管理。
  • 吸烟史可用于IIM患者肌外受累及疾病严重程度的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data. METHODS: Cross-sectional analysis of IIM cases from 11 countries was performed. Associations between clinical subtypes, extramuscular involvement, environmental exposures and medications were investigated. RESULTS: Of 3067 IIM cases, 69% were female. The most common IIM subtype was dermatomyositis (DM) (31%). Smoking was more frequent in connective tissue disease overlap cases (45%, OR 1.44, 95% CI 1.09 to 1.90, p=0.012). Smoking was associated with interstitial lung disease (ILD) (OR 1.32, 95% CI 1.06 to 1.65, p=0.013), dysphagia (OR 1.43, 95% CI 1.16 to 1.77, p=0.001), malignancy ever (OR 1.78, 95% CI 1.36 to 2.33, p<0.001) and cardiac involvement (OR 2.40, 95% CI 1.60 to 3.60, p<0.001).Dysphagia occurred in 39% and cardiac involvement in 9%; either occurrence was associated with higher Health Assessment Questionnaire (HAQ) scores (adjusted OR 1.79, 95% CI 1.43 to 2.23, p<0.001). HAQ scores were also higher in inclusion body myositis cases (adjusted OR 3.85, 95% CI 2.52 to 5.90, p<0.001). Malignancy (ever) occurred in 13%, most commonly in DM (20%, OR 2.06, 95% CI 1.65 to 2.57, p<0.001).ILD occurred in 30%, most frequently in antisynthetase syndrome (71%, OR 10.7, 95% CI 8.6 to 13.4, p<0.001). Rash characteristics differed between adult-onset and juvenile-onset DM cases ('V' sign: 56% DM vs 16% juvenile-DM, OR 0.16, 95% CI 0.07 to 0.36, p<0.001). Glucocorticoids were used in 98% of cases, methotrexate in 71% and azathioprine in 51%. CONCLUSION: This large multicentre cohort demonstrates the importance of extramuscular involvement in patients with IIM, its association with smoking and its influence on disease severity. Our findings emphasise that IIM is a multisystem inflammatory disease and will help inform prognosis and clinical management of patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2017. PMID: 28855174. doi:10.1136/annrheumdis-2017-211868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。